NCS Multistage (NCSM) Q1 2026 earnings review
Top-Line Miss as Canadian Collapse Overshadows U.S. Strength
NCS Multistage broke its streak of double-digit growth quarters with an 8.7% YoY revenue contraction in 26Q1, entirely missing its own $49M-$53M guidance by coming in at $45.6M. The culprit was a severe 38% decline in the Canadian market driven by falling rig counts and abrupt project deferrals. While the U.S. segment was a bright spot—doubling its revenue on the back of the ResMetrics acquisition and strong Repeat Precision product adoption—it was not enough to prevent sharp margin compression. Adjusted EBITDA dropped 32% YoY. The sole silver lining was disciplined cash management: despite the earnings miss, the company squeezed out positive Free Cash Flow during a quarter that traditionally burns cash.
🐂 Bull Case
U.S. revenue skyrocketed 104% YoY to $19.1M. New product field trials successfully converted into sales, and the ResMetrics integration is contributing immediately to the top line.
Despite a drop in net income, Free Cash Flow reversed from negative $2.1M a year ago to positive $0.7M. The balance sheet remains bulletproof with over $27M in net cash.
🐻 Bear Case
Canada is NCS's historical profit engine, and a 38% YoY revenue plunge indicates severe macro weakness and customer hesitation that cannot be easily offset by the U.S. business.
The massive drop in Canadian volume crushed fixed cost absorption. Adjusted gross margin fell from 44% to 40%, and Adjusted EBITDA margin contracted from 16% to 12%.
⚖️ Verdict: 🔴
Bearish. Management praised their 'solid execution,' but the numbers show a definitive guidance miss and a complete breakdown in the Canadian market. U.S. growth is impressive but insufficient to carry the consolidated bottom line.
Key Themes
Canadian Market Collapse
Reversing. After posting steady gains in early 2025, the Canadian segment fell off a cliff, dropping 38% YoY to $23.2M. Management cited lower industry activity, reduced rig counts, and sudden customer-specific job deferrals in March. This represents a significant break in trend and raises red flags about North American capital expenditure budgets for the rest of the year.
Profitability Reversal Contradicts Narrative
Decelerating. Management's press release cited 'solid execution and momentum,' but the actual data contradicts this positive spin. Q1 revenue of $45.6M outright missed the company's previously stated guidance of $49M-$53M. Consequently, Adjusted EBITDA fell 32% YoY to $5.6M (missing the $6.5M-$8.5M guide). The fixed cost absorption hit from lower sales volume is severely damaging the bottom line.
U.S. Segment Resurgence & Product Innovation
Accelerating. The U.S. business is structurally stronger, with revenue jumping 104% YoY to $19.1M. Growth is driven by field trial successes converting to sales, specifically highlighting the proprietary StageSaver composite and PurpleReign dissolvable frac plugs. The integration of ResMetrics ($1.8M contribution this quarter) further bolsters this momentum.
Free Cash Flow Inflection
Reversing. Historically, Q1 is a cash-consumptive period due to bonus payouts and working capital builds. However, Operating Cash Flow flipped from $(1.6)M in 25Q1 to +$1.3M in 26Q1. This highlights excellent financial discipline and cost management even as the top line deteriorated.
ResMetrics Integration & Cost Discipline
Stable. SG&A expenses actually decreased by $0.5M YoY to $15.7M, despite absorbing the overhead of the newly acquired ResMetrics business. Lower bonus accruals and share-based compensation helped offset the added operational weight, validating management's synergy targets.
Unpredictable International Project Timing
Decelerating. International revenues (Other Countries) grew slightly overall ($3.3M vs $2.9M YoY) due to product sales, but management flagged decreased service revenue specifically tied to tracer diagnostic project delays in the Middle East. This highlights the lumpiness and unpredictability of international expansion.
Other KPIs
Up from $59.1M at the end of 25Q4. The increase was primarily driven by higher inventory levels (now at $40.8M). This inventory build during a period of declining sales is a point to monitor, as it suggests the company was caught off guard by the abrupt project deferrals in Canada.
Reversing from a $4.1M profit in 25Q1. Margins collapsed due to product mix and the steep drop in Canadian volume. Higher tax expenses (driven by deferred tax expense on assets previously protected by a valuation allowance) further dragged earnings into negative territory.
Guidance
Stable. The CEO explicitly stated they 'remain confident in our full year 2026 outlook.' While numbers weren't reprinted in this release, the previous 25Q4 call established a $184M-$194M revenue target. Achieving this after a $45.6M Q1 miss requires significant acceleration in H2. Management expects a 'modest year-over-year increase' in Canadian activity in H2 to offset the Q1 shortfall, making the back half of the year highly execution-dependent.
Key Questions
Visibility on Deferred Canadian Projects
You missed Q1 revenue guidance by over $3M, yet reaffirmed confidence in the full-year outlook. What specific commercial commitments give you visibility that the deferred March projects in Canada will actually materialize in H2 rather than being canceled outright?
Inventory Management Divergence
Inventory levels increased sequentially to $40.8M despite a 10% sequential drop in revenue. Was this buildup a strategic decision anticipating H2 demand, or simply a byproduct of unexpected project cancellations in Q1?
U.S. Organic Run Rate
The U.S. segment grew 104% YoY. If we strip out the $1.8M contribution from ResMetrics, how much of the remaining organic growth is sustainable recurring revenue from StageSaver/PurpleReign versus one-off stocking orders?